PCSK9 inhibitors don't universally lower hsCRP ( https://pmc.ncbi.nlm.nih.gov/articles/PMC4876179/ https://pmc.ncbi.nlm.nih.gov/articles/PMC4876179/ ) but do lo

PCSK9 inhibitors don't universally lower hsCRP ( https://pmc.ncbi.nlm.nih.gov/articles/PMC4876179/ https://pmc.ncbi.nlm.nih.gov/articles/PMC4876179/ ) but do lower adverse cardiovascular events https://pubmed.ncbi.nlm.nih.gov/36779348/ https://pubmed.ncbi.nlm.nih.gov/36779348/ MR studies looking at genetics show a decrease in cardiovascular events with lower LDL/Lp(a) levels independent of other factors such as hsCRP https://pubmed.ncbi.nlm.nih.gov/23083789/ https://pubmed.ncbi.nlm.nih.gov/23083789/ https://www.nejm.org/doi/full/10.1056/NEJMoa1604304 https://www.nejm.org/doi/full/10.1056/NEJMoa1604304 https://journals.plos.org/plosmedicine/article%3Fid%3D10.1371/journal.pmed.1003062 https://journals.plos.org/plosmedicine/article%3Fid%3D10.137... Lp(a), another plaque depositing particle also has been shown in MR to be an independent risk factor for CVD events regardless of hsCRP https://europepmc.org/article/med/20032323 https://europepmc.org/article/med/20032323 https://pmc.ncbi.nlm.nih.gov/articles/PMC5483508/ https://pmc.ncbi.nlm.nih.gov/articles/PMC5483508/ https://www.nejm.org/doi/full/10.1056/NEJMoa1109034 https://www.nejm.org/doi/full/10.1056/NEJMoa1109034